Literature DB >> 1951473

Persisting renotubular sequelae after cisplatin in children and adolescents.

M G Bianchetti1, C Kanaka, A Ridolfi-Lüthy, A Hirt, H P Wagner, O H Oetliker.   

Abstract

UNLABELLED: Information on persisting renal sequelae after cisplatin in children and adolescents is limited. Twelve patients aged 4-20 years had been treated with cisplatin and were healthy 4-43 months after stopping chemotherapy. Plasma creatinine, calcium, albumin and hydrogen ion concentration, plasma and urinary sodium, chloride, phosphate and urate, and urinary magnesium and potassium were comparable in patients and controls. However, mean calciuria, magnesemia and potassemia were significantly reduced and bicarbonatemia increased in the patients. Calciuria, magnesemia, potassemia and bicarbonatemia were normal in 3 patients only, calciuria was below -2 SD control in 9 patients, renal magnesium deficiency was demonstrated in 5 patients (all with hypocalciuria as well), and 4 patients presented with hypokalemic metabolic alkalosis (all with magnesium deficiency and hypocalciuria).
CONCLUSIONS: (1) Renotubular dysfunctions persist very often after cisplatin; (2) hypocalciuria is more frequent than hypomagnesemia; (3) the most severe tubulopathy after cisplatin includes hypocalciuria, renal magnesium deficiency and hypokalemic metabolic alkalosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951473     DOI: 10.1159/000168288

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  10 in total

Review 1.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.

Authors: 
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

Review 3.  Imaging of late complications of cancer therapy in children.

Authors:  Susan C Shelmerdine; Govind B Chavhan; Paul S Babyn; Paul C Nathan; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2016-12-01

Review 4.  Risk-based health monitoring of childhood cancer survivors: a report from the Children's Oncology Group.

Authors:  Susan B Nunez; Daniel A Mulrooney; Caroline Laverdiere; Melissa M Hudson
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

5.  Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines.

Authors:  Wendy Landier; Saro H Armenian; Jin Lee; Ola Thomas; F Lennie Wong; Liton Francisco; Claudia Herrera; Clare Kasper; Karla D Wilson; Meghan Zomorodi; Smita Bhatia
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

6.  Magnesium metabolism and its disorders.

Authors:  R Swaminathan
Journal:  Clin Biochem Rev       Date:  2003-05

7.  Yield of Urinalysis Screening in Pediatric Cancer Survivors.

Authors:  Matthew D Ramirez; Ann C Mertens; Natia Esiashvili; Lillian R Meacham; Karen Wasilewski-Masker
Journal:  Pediatr Blood Cancer       Date:  2016-01-21       Impact factor: 3.167

8.  Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.

Authors:  Lisa M McGregor; Sheri L Spunt; Victor M Santana; Clinton F Stewart; Deborah A Ward; Amy Watkins; Fred H Laningham; Percy Ivy; Wayne L Furman; Maryam Fouladi
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

9.  Outcomes of kidney injury including dialysis and kidney transplantation in pediatric oncology and hematopoietic cell transplant patients.

Authors:  Natalie L Wu; Sangeeta Hingorani
Journal:  Pediatr Nephrol       Date:  2021-01-07       Impact factor: 3.714

Review 10.  Gitelman-like syndrome after cisplatin therapy: a case report and literature review.

Authors:  Kessarin Panichpisal; Freddy Angulo-Pernett; Sharmila Selhi; Kenneth M Nugent
Journal:  BMC Nephrol       Date:  2006-05-24       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.